Table 2.
Response to abrocitinib treatment at week 12 and maintenance of response at week 16
| Responders at week 12, n (%) | Maintained response at week 16, n | Did not maintain response at week 16, n | Total assessed for response maintenance, n | Maintained response at week 16, % | |
|---|---|---|---|---|---|
| EASI-50 (N = 109)a | |||||
| Placebo | 14 (12.8) | 8 | 0 | 8 | 100 |
| Abrocitinib 100 mg | 30 (27.5) | 14 | 13 | 27 | 51.9 |
| Abrocitinib 200 mg | 38 (34.9) | 24 | 7 | 31 | 77.4 |
| EASI-75 (N = 75)a | |||||
| Placebo | 8 (10.7) | 6 | 1 | 7 | 85.7 |
| Abrocitinib 100 mg | 22 (29.3) | 7 | 13 | 20 | 35.0 |
| Abrocitinib 200 mg | 31 (41.3) | 11 | 15 | 26 | 42.3 |
| IGA (N = 49)a | |||||
| Placebo | 3 (6.1) | 2 | 0 | 2 | 100.0 |
| Abrocitinib 100 mg | 16 (32.7) | 5 | 10 | 15 | 33.3 |
| Abrocitinib 200 mg | 21 (42.9) | 4 | 15 | 19 | 21.1 |
| Pruritus NRS4 (N = 91)a | |||||
| Placebo | 13 (14.3) | 5 | 1 | 6 | 83.3 |
| Abrocitinib 100 mg | 25 (27.5) | 10 | 13 | 23 | 43.5 |
| Abrocitinib 200 mg | 28 (30.8) | 9 | 12 | 21 | 42.9 |
EASI-50, EASI-75 50% and 75% improvement in the Eczema Area and Severity Index, respectively, IGA Investigator’s Global Assessment, pruritus NRS4 4-point or greater improvement in baseline pruritus numeric rating scale score
aThe number of total responders at week 12 includes patients who received abrocitinib 10 mg and 30 mg